Equities

Lyra Therapeutics Inc

LYRA:NMQ

Lyra Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.275
  • Today's Change0.01 / 3.77%
  • Shares traded1.16m
  • 1 Year change-90.83%
  • Beta-0.0402
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1039846
Total Receivables, Net------
Total Inventory------
Prepaid expenses2.072.942.17
Other current assets, total------
Total current assets10510148
Property, plant & equipment, net354.475.86
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets14311055
LIABILITIES
Accounts payable3.132.623.13
Accrued expenses15115.33
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total1.661.289.79
Total current liabilities201418
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total34152.31
Total liabilities532921
SHAREHOLDERS EQUITY
Common stock0.060.030.01
Additional paid-in capital401329228
Retained earnings (accumulated deficit)(311)(249)(193)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.030.01--
Total equity898134
Total liabilities & shareholders' equity14311055
Total common shares outstanding573213
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.